Guideline for Resuming Weekly Vitamin D₃ 50,000 IU After Accidental Daily Dosing
1. Treatment Regimen Adjustment
- The standard therapeutic course for vitamin D deficiency is 50,000 IU of vitamin D₃ taken once weekly for 8 weeks (total ≈ 400,000 IU) as recommended by the Endocrine Society 3.
- After an accidental intake of 300,000 IU over 6 days, the first 5 weeks of the planned 8‑week course should be omitted (i.e., hold all vitamin D supplementation) to avoid cumulative overdose 6.
- Weekly dosing (50,000 IU) should be resumed in week 6 to complete the remaining two doses of the original 8‑week regimen 4.
- Upon completion of the adjusted 8‑week course, maintenance therapy of 1,500–2,000 IU daily is advised for most adults 3.
2. Monitoring Recommendations
- Serum calcium check – If the patient develops symptoms suggestive of hypercalcemia (e.g., nausea, confusion, polyuria, constipation), obtain a serum calcium measurement within 1–2 weeks 2.
- 25‑hydroxyvitamin D measurement – Obtain a 25(OH)D level at weeks 3–4 (just before resuming weekly dosing) to ensure concentrations are not excessive 1.
- Target 25(OH)D range – Aim for 30–44 ng/mL; values >70 ng/mL should trigger dose reduction or delay of resumption 1.
- If 25(OH)D > 70 ng/mL at week 3–4, postpone restarting weekly dosing and repeat the level in 2–4 weeks 1.
- Long‑term follow‑up – Re‑measure 25(OH)D three months after finishing the treatment course to confirm the target range of 30–44 ng/mL is maintained 1.
3. Safety Considerations
- A single 300,000 IU dose is well below documented toxic thresholds; even doses up to 2,000,000 IU have produced only mild, transient hypercalcemia without clinical toxicity 1.
- Toxicity is unlikely unless 25(OH)D exceeds 100 ng/mL; doses of 500,000 IU annually or 50,000 IU weekly rarely cause hypercalcemia in the absence of such high serum levels 1.
- Weekly dosing (50,000 IU) is considered safer than daily high‑dose regimens, as endorsed by the Endocrine Society 3.
- Active vitamin D analogs (e.g., calcitriol, alfacalcidol) should be avoided for correction of the overdose because they bypass physiological regulation and markedly increase hypercalcemia risk 2.
- Annual high‑dose bolus regimens (≈ 500,000 IU) have been linked to an increased fracture risk and should be avoided in this context 1.
4. Special Populations
| Population | Modified Recommendation | Evidence |
|---|---|---|
| Obese adults | Maintenance dose may need to be 2–3 × higher (≈ 3,000–6,000 IU daily) after treatment completion | 3 |
| Patients with malabsorption or on enzyme‑inducing drugs | Same higher maintenance dose (≈ 3,000–6,000 IU daily) | 3 |
| Granulomatous disease or primary hyperparathyroidism | Implement closer serum calcium monitoring due to heightened hypercalcemia risk | 3 |
5. Transition to Maintenance Therapy
- Standard maintenance – 1,500–2,000 IU daily for most adults after the adjusted 8‑week course 3.
- Alternative intermittent schedule – 50,000 IU every 2 weeks provides an equivalent total dose and may improve adherence 3.
- Re‑assessment – Check 25(OH)D at 3 months to verify levels remain within the optimal 30–44 ng/mL window 1.